Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concerta XL for ADHD symptoms and behavioral problems in young male offenders with ADHD
ISRCTN16827947Phase 4Completed
- Sponsor
- King's College London
- Start
- Oct 2016
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of methylphenidate hydrochloride OROS in attention deficit hyperactivity disorder (ADHD), sponsored by King's College London. Primary endpoint: ADHD symptoms at 8 weeks. Started Oct 2016; status: completed.
02
Drugs
methylphenidate hydrochloride OROS
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on ISRCTN16827947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16827947.